Compare CINF & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CINF | GMAB |
|---|---|---|
| Founded | 1950 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4B | 21.1B |
| IPO Year | N/A | N/A |
| Metric | CINF | GMAB |
|---|---|---|
| Price | $156.52 | $34.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $177.25 | $40.00 |
| AVG Volume (30 Days) | 562.7K | ★ 2.0M |
| Earning Date | 02-09-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | N/A | ★ 132.41 |
| EPS | 13.44 | ★ 25.10 |
| Revenue | ★ $12,078,000,000.00 | $3,845,670,022.00 |
| Revenue This Year | $10.47 | $24.85 |
| Revenue Next Year | N/A | $16.51 |
| P/E Ratio | $11.75 | ★ $1.33 |
| Revenue Growth | N/A | ★ 29.57 |
| 52 Week Low | $123.02 | $17.24 |
| 52 Week High | $169.86 | $35.43 |
| Indicator | CINF | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 58.27 |
| Support Level | $155.14 | $30.88 |
| Resistance Level | $159.64 | $33.92 |
| Average True Range (ATR) | 2.83 | 0.97 |
| MACD | -0.69 | 0.00 |
| Stochastic Oscillator | 13.65 | 80.99 |
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The company operates in segments: Commercial lines insurance, Personal lines insurance, and Excess and surplus lines insurance, Life insurance, and Investments. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.